Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention

Cancer Biology and Medicine

Volumn 11, Issue 1, 2014, Pages 44-55

  Garbuzenko, Olga B ^a   Mainelis, Gediminas ^b,c   Taratula, Oleh ^a,d   Minko, Tamara ^a,c,e  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Drug delivery systems; Inhalation administration; Intravenous administration; Lung neoplasms; Nanoparticles

Indexed keywords

AZETIDINE; DENDRIMER; DOXORUBICIN; LIPOSOME; MACROGOL; NANOCARRIER; QUANTUM DOT; SILICA NANOPARTICLE; SILICON DIOXIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RETENTION; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; LIVER; LUNG CANCER; LUNG PARENCHYMA; MAXIMUM TOLERATED DOSE; MICELLE; MOUSE; NONHUMAN; SPLEEN; ZETA POTENTIAL;

EID: 84897931737     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2014.01.004     Document Type: Article

References (40)

1. Melani A S. Inhalatory therapy training: a priority challenge for the physician. Acta Biomed 2007;78:233-245.
2. Kane C, O'Neil K, Conk M, Picha K. Inhalation delivery of protein therapeutics. Inflamm Allergy Drug Targets 2013;12:81-87.
3. Labiris N R, Dolovich M B. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:600-612.
4. Savla R, Minko T. Nanotechnology approaches for inhalation treatment of fibrosis. J Drug Target 2013;21:914-925.
5. Johnson M D, Widdicombe J H, Allen L, Barbry P, Dobbs L G. Alveolar epithelial type I cells contain transport proteins and transport sodium, supporting an active role for type I cells in regulation of lung liquid homeostasis. Proc Natl Acad Sci U S A 2002;99:1966-1971.
6. Labiris N R, Dolovich M B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-599.
7. Valle M J, González López F, Sánchez Navarro A. Pulmonary versus systemic delivery of levofloxacin. The isolated lung of the rat as experimental approach for assessing pulmonary inhalation. Pulm Pharmacol Ther 2008;21:298-303.
8. Ivanova V, Garbuzenko O B, Reuhl K R, Reimer D C, Pozharov V P, Minko T. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur J Pharm Biopharm 2013;84:335-344.
9. Minko T, Stefanov A, Pozharov V. Selected contribution: Lung hypoxia: antioxidant and antiapoptotic effects of liposomal alpha-tocopherol. J Appl Physiol (1985) 2002;93:1550-1560; discussion 1549.
10. Garbuzenko O B, Saad M, Betigeri S, Zhang M, Vetcher A A, Soldatenkov V A, et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res 2009;26:382-394.
11. Garbuzenko O B, Saad M, Pozharov V P, Reuhl K R, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A 2010;107:10737-10742.
12. Minko T, Rodriguez-Rodriguez L, Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev 2013;65:1880-1895.
13. Sung J C, Pulliam B L, Edwards D A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007;25:563-570.
14. Yang W, Peters J I, Williams R O 3rd. Inhaled nanoparticles - a current review. Int J Pharm 2008;356:239-247.
15. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008;26:57-64.
16. Taratula O, Garbuzenko O B, Chen A M, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 2011;19:900-914.
17. Taratula O, Kuzmov A, Shah M, Garbuzenko O B, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 2013;171:349-357.
18. Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr C M, Ehrhardt C. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 2006;29:367-374.
19. Anabousi S, Kleemann E, Bakowsky U, Kissel T, Schmehl T, Gessler T, et al. Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J Nanosci Nanotechnol 2006;6:3010-3016.
20. Koshkina N V, Waldrep J C, Roberts L E, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001;7:3258-3262.
21. Tong S W, Xiang B, Dong D W, Qi X R. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles. Int J Pharm 2012;434:413-419.
22. Zhao B J, Ke X Y, Huang Y, Chen X M, Zhao X, Zhao B X, et al. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. J Drug Target 2011;19:382-390.
23. Taratula O, Garbuzenko O B, Kirkpatrick P, Pandya I, Savla R, Pozharov V P, et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 2009;140:284-293.
24. Patil M L, Zhang M, Taratula O, Garbuzenko O B, He H, Minko T. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules 2009;10:258-266.
25. Shcharbin D, Shakhbazau A, Bryszewska M. Poly(amidoamine) dendrimer complexes as a platform for gene delivery. Expert Opin Drug Deliv 2013;10:1687-1698.
26. Chandna P, Khandare J J, Ber E, Rodriguez-Rodriguez L, Minko T. Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers. Pharm Res 2010;27:2296-2306.
27. Shah V, Taratula O, Garbuzenko O B, Taratula O R, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 2013;19:6193-6204.
28. He Q, Shi J. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv Mater 2014;26:391-411.
29. Chen A M, Zhang M, Wei D, Stueber D, Taratula O, Minko T, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009;5:2673-2677.
30. Mainelis G, Seshadri S, Garbuzenko O B, Han T, Wang Z, Minko T. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice. J Aerosol Med Pulm Drug Deliv 2013;26:345-354.
31. Shah V, Taratula O, Garbuzenko O B, Patil M L, Savla R, Zhang M, et al. Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Curr Drug Discov Technol 2013;10:8-15.
32. Saad M, Garbuzenko O B, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 2008;3:761-776.
33. Zhang M, Garbuzenko O B, Reuhl K R, Rodriguez-Rodriguez L, Minko T. Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine (Lond) 2012;7:185-197.
34. Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release 2011;153:16-22.
35. Saad M, Garbuzenko O B, Ber E, Chandna P, Khandare J J, Pozharov V P, et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 2008;130:107-114.
36. Pakunlu R I, Wang Y, Saad M, Khandare J J, Starovoytov V, Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006;114:153-162.
37. Wang Y, Saad M, Pakunlu R I, Khandare J J, Garbuzenko O B, Vetcher A A, et al. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor. Clin Cancer Res 2008;14:3607-3616.
38. Garbuzenko O, Zalipsky S, Qazen M, Barenholz Y. Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers. Langmuir 2005;21:2560-2568.
39. Hong H, Chen F, Cai W. Pharmacokinetic issues of imaging with nanoparticles: focusing on carbon nanotubes and quantum dots. Mol Imaging Biol 2013;15:507-520.
40. Li S D, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008;5:496-504.